GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+7.25%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$0.84
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.91
- EPS estimate
- -$1.19
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +3.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $19
- PT range
- $10 – $27
- Analysts
- 3
3 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$1.19 | -$0.91 | Beat 23.53% | — |
| May 13, 2026 | -$0.91 | -$1.61 | Miss -76.92% | — |
| Mar 13, 2026 | -$29 | -$5.34 | Beat 81.74% | — |
| Nov 14, 2025 | -$31 | -$36 | Miss -15.31% | $6.3M |
| Aug 14, 2025 | -$1.31 | -$1.31 | In line | $22.5M |
| May 15, 2025 | -$4.11 | -$5.80 | Miss -41.12% | — |
| Dec 16, 2024 | — | -$320 | — | — |
| Aug 13, 2024 | — | -$84 | — | — |
| May 10, 2024 | — | -$102 | — | — |
| Aug 14, 2023 | — | -$4.3K | — | — |
| May 15, 2023 | — | -$8.2K | — | — |
| Feb 24, 2023 | -$13.5K | -$0.10 | Beat 100.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026